Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | STK11 mutant |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 pos STK11 mut | lung non-small cell carcinoma | predicted - resistant | unspecified PD-1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, non-small cell lung carcinoma patients positive for CD274 and harboring an STK11 mutation treated with a PD-1 inhibitor demonstrated a lower objective response rate compared to CD274-positive patients with wild-type STK11, 0% (0/11) vs 34.5% (19/55), respectively (PMID: 29773717). | 29773717 |
KEAP1 mut STK11 mut | lung adenocarcinoma | not predictive | unspecified PD-1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, lung adenocarcinoma patients harboring both a KEAP1 mutation and STK11 mutation demonstrated a shorter progression free survival compared to patients with wild-type KEAP1 and wild-type STK11 when treated with an unspecified PD-1 antibody treatment, but when compared to other treatments, all were associated with shorter progression free survival (PMID: 32312757). | 32312757 |
KEAP1 mut STK11 mut | lung adenocarcinoma | not predictive | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, lung adenocarcinoma patients harboring both a KEAP1 mutation and STK11 mutation demonstrated a shorter progression free survival compared to patients with wild-type KEAP1 and wild-type STK11 when treated with an unspecified PD-L1 antibody treatment, but when compared to other treatments, all were associated with shorter progression free survival (PMID: 32312757). | 32312757 |
CD274 over exp STK11 mut | lung adenocarcinoma | not predictive | unspecified immune checkpoint inhibitor | Clinical Study - Cohort | Actionable | In a clinical study, lung adenocarcinoma patients with high expression of CD274 (PD-L1; >/= 50%) and a co-occurring STK11 mutation demonstrated a similar objective response rate (P=0.2), progression-free survival (P=0.29), and overall survival (0.44) compared to patients with negative expression of CD274 (PD-L1) and a co-occurring EGFR mutation when treated with an unspecified immune checkpoint inhibitor (PMID: 32178965). | 32178965 |
CD274 pos STK11 mut | lung non-small cell carcinoma | not predictive | Pembrolizumab | Clinical Study | Actionable | In a retrospective analysis of a Phase III trial (KEYNOTE-042), Keytruda (pembrolizumab) treatment resulted in a similar improved overall survival compared to chemotherapy in patients with CD274 (PD-L1)-positive non-small cell lung cancer with either an STK11 mutation (HR=0.37) or wild-type STK11 (HR=0.83) (PMID: 36709038; NCT02220894). | 36709038 |